The nano-level surface structure “NanoSpike” technology, which semi-permanently inactivates microorganisms, is inspired by the microscopic structures found on cicada wings. It is a new form of “physical antimicrobial technology” that destroys bacteria and viruses without the use of chemicals. From infection control to medical care, space applications, and everyday life, it delivers safer and more sustainable solutions across a wide range of fields.
We are a biotech company leveraging technologies from the National Cerebral and Cardiovascular Center, Nagasaki University, and Osaka University. We are developing "BROTHERS," a proprietary technology that pairs a PNA strand with an antisense oligonucleotide (ASO). This PNA acts as a "safeguard" to significantly reduce the toxicity issues common in conventional oligonucleotide therapeutics. We drive growth through a dual-engine business model: advancing our in-house pipeline for intractable diseases and out-licensing our platform via collaborations with pharmaceutical companies.
CarbGeM is driving innovation in the life sciences through cutting-edge technologies, including regulatory-approved Software as a Medical Device (SaMD). The company empowers diagnostic support, research efficiency, and the standardization and automation of quality control. While addressing social challenges such as a shortage of skilled professionals and regional healthcare disparities, CarbGeM supports medical and industrial sectors by providing accurate and rapid results. Leveraging AI and digital platforms, the company fosters collaboration among healthcare professionals and researchers worldwide. CarbGeM is actively engaged in co-creating the future of medicine and science through open innovation with leading institutions across industry, academia, and government. The company has received numerous honors, including the Tokyo Social Innovation Tech Award 2024.
We offer technology licensing to various companies for a "perfect alcohol-based sanitizer" effective against food poisoning bacteria that are resistant to standard alcohol sanitizers. The reason these bacteria survive even at 100℃ is their ability to synthesize a robust structure called a spore. We have discovered that substance Y inhibits spore formation, and by incorporating it into alcohol-based sanitizers sterilization becomes possible. Furthermore, substance Y is safe and secure; when added to food products, the bacteria can be killed by heating at 100℃. We are therefore also proposing a new sterilization method.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.